WASHINGTON (CNN) -- New "super aspirin" can effectively relieve angina and significantly reduce the risk of heart attacks, according to a study published Monday.

The study, in Circulation: Journal of the American Heart Association, looked at Lamifiban, a drug now in its last phase of testing before a final review by the U.S. Food and Drug Administration.

The first "super aspirin," Aggrastat, was approved by the FDA last month and is now in distribution.

The current treatment for angina -- chest pain caused by a poor blood supply to the heart muscle -- is conventional aspirin and a blood-thinning drug called heparin. The aspirin-heparin combination does not work in at least 10 percent of cases, and some patients go on to have a heart attack.

Unstable angina occurs when years of cholesterol buildup on artery walls suddenly causes a rupture and platelets clump around the wound. As the clot becomes larger, it blocks arterial blood flow to the heart and can lead to a heart attack.

Studies show that the new "super aspirin" drugs, especially when used in combination with aspirin and heparin, can significantly reduce the incidence of angina and heart attacks.

The latest study shows that Lamifiban has a greater long-term benefit rather than an immediate effect, meaning that it may not give a quick response when dealing with angina in an emergency situation. Angina is the leading reason for admitting people to coronary care units.

"Other things being equal, doctors will tend to use Aggrastat instead of Lamifiban because the immediate results with Aggrastat appear to be better than the results of Lamifiban," said Dr. Alan Geurci of St. Francis Hospital in Roslyn, New York. "Manufacturers of Lamifiban are going to have a hard sell."

Lamifiban is in Phase III clinical trials, which is usually the last step before seeking FDA approval. It will not be ready for distribution "at least until next year," according to its manufacturer, Hoffman-LaRouche Inc.

Aggrastat is manufactured by Merck & Co.